Loading patent…
AssigneesAcceleron Pharma Inc., Ludwig Institute for Cancer Research
InventorsAsya Grinberg, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra, Kristian Pietras
Estimating the term…
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.
-8. (canceled)
A method for inhibiting angiogenesis in a mammal in need thereof, the method comprising administering to the mammal an effective amount of a pharmaceutical preparation comprising an ALK1-Fc fusion protein comprising:
-12. (canceled)
A method of promoting an increase in pericyte coverage in a vascularized tissue of a mammal in need thereof, the method comprising administering to the mammal an effective amount of an ALK1 ECD protein.
-39. (canceled)
A method for treating a tumor in a mammal, the method comprising, administering to a mammal that has a tumor an effective amount of an agent selected from the group consisting of:
-60. (canceled)
Dependencies are inferred from the claim text.